2nd Quarter - Report

CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
—
Expenses
$150,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Oppose medical device tariffs Support data exclusivity provisions in USMCA / Oppose proposals to reduce data exclusivity

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN New —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Support FDA user fee programs and review process consistency and predictability. Support PAHPA reauthorization. Support policy improvements to address antimicrobial resistance.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN New —

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

Support NIH research funding Support implementation of 21st Century Cures Act

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN New —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Copyright/Patent/Trademark CPT

Address concerns with provisions of patent litigation reform, including inter partes review Support STRONGER Patents Act Support Hatch Waxman Integrity Act Oppose "march-in" rights and "compulsory licensing" proposals

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN New —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Support repeal of medical device tax Support orphan drug tax credit and R & D tax credit

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN New —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System Address concerns with Medicare Advantage step therapy proposal and Medicare Part D protected classes proposal Oppose changes to Medicare Advantage and Part D prescription drug benefit Support reforms to enable Value Based Healthcare Oppose International Pricing Index/reference pricing in Medicare Part B Support Ensuring Patient Access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System proposed rule and legislation Oppose Medicare negotiating proposals that include compulsory licensing

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN New —

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Budget/Appropriations BUD

Labor/HHS/Ed Appropriations: NIH, antimicrobial resistance, biodefense/pandemic, science/math education, and strategic stockpile funding and preparation FDA Appropriations; PTO Appropriations

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN New —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.